Stock AnalizThermo Fisher Scientific Inc. TMO
Industrial Machinery/Components · data as of November 13, 2026
Thermo Fisher Scientific Inc. (TMO) is a industrial company listed in the US with a market value of about $259.4B. In the twelve months to September 26, 2026 it had revenue of $47.4B and net income of $7.1B, a net margin of 14.9%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is shareholder returns (5/5); the weakest is value (0/5).
Key numbers: a P/E of 36.9, a price to free cash flow of 34.2, 5-year revenue growth of 7% a year, a 5-year average ROIC of 9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 51% below the current price.
Score: 2.0 / 5
Checks passed
- Profit margin improving
- Profitable 5 years in a row
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
- Pays a dividend
- Share count down over 3 years (buybacks)
- 20% to 100% of free cash flow returned to shareholders
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $47.4B | $44.6B | $42.9B | $42.9B | $44.9B | $39.2B | $32.2B | $25.5B | $24.4B | $20.9B | $18.3B |
| Net income | $7.1B | $6.7B | $6.3B | $6.0B | $7.0B | $7.7B | $6.4B | $3.7B | $2.9B | $2.2B | $2.0B |
| Free cash flow | $7.6B | $6.3B | $7.3B | $6.9B | $6.9B | $6.8B | $6.8B | $4.0B | $3.8B | $3.5B | $2.8B |
| EPS (diluted) | $18.96 | $17.74 | $16.53 | $15.45 | $17.63 | $19.46 | $15.96 | $9.17 | $7.24 | $5.59 | $5.09 |
| Net margin | 14.9% | 15.0% | 14.8% | 14.0% | 15.5% | 19.7% | 19.8% | 14.5% | 12.1% | 10.6% | 11.1% |
| ROIC | — | 7.6% | 8.1% | 7.9% | 9.5% | 11.4% | 12.0% | 8.7% | 7.3% | 5.8% | 5.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 25 analysts is $756.52, 8% above the current price; targets range from $590.00 to $830.00; the consensus rating is “Strong buy”; expected EPS is $25.28 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Thermo Fisher Scientific’s P/E ratio?
About 36.9, based on the last twelve months of diluted earnings per share (forward P/E about 25.9).
Is Thermo Fisher Scientific stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 51% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Thermo Fisher Scientific pay a dividend?
Yes. The dividend yield is about 0.26%, and it has paid dividends for 10 years in our data.
Is Thermo Fisher Scientific a good stock to buy?
We do not give buy or sell advice. Thermo Fisher Scientific scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.